Female Testosterone Patch for HSDD: The Precision Medicine Gap of FDA Non-Approval and Off-Label Prescribing

Female hypoactive sexual desire disorder (HSDD) affects 25~30% of menopausal women — a common clinical situation. But the absence of FDA-approved standard treatment is one example of precision medicine’s gap. The 2025 VA Formulary, JAMA Internal Medicine RCTs, and Medherant TEPI patch phase 1 data converge on one trend: transdermal testosterone has clinical efficacy data but is FDA non-approved, used through physician off-label prescribing.

What Is HSDD

A diagnosis under female sexual dysfunction. DSM-5 integrated as “Female Sexual Interest/Arousal Disorder.” Core criteria:

• Meaningful reduction in sexual desire·interest
• Distress or interpersonal difficulty around sexual relations
• Persistence 6+ months
• Other medical·psychiatric causes excluded (depression, drug side effects, thyroid, etc.)

Impact:

• 2530% of menopausal women (810% of all women)
• Accelerated post-menopause (concurrent estrogen + testosterone decline)
• More severe after surgical menopause (oophorectomy)
• Broad effects on relationships·psychology·quality of life

Testosterone and Women

Testosterone is not just a male hormone — it’s also a female hormone. In women, testosterone:

• Ovaries (50%): partial maintenance post-menopause
• Adrenal glands (50%): lifelong secretion (slow decline)
• Blood concentration: reproductive years 0.30.7 ng/mL, post-menopause 0.10.3 ng/mL
• Function: libido, muscle strength, bone density, mood, cognition

Clinical signals of female testosterone deficiency:

• Reduced libido + reduced sexually satisfying events
• Chronic fatigue
• Muscle·bone loss
• Mood depression
• Cognitive fog

Clinical Data

JAMA Internal Medicine RCT (2005, surgical menopause patients):

• Transdermal testosterone patch 300 μg/day for 6 months
• Meaningful increase in sexually satisfying events vs placebo
• Increased sexual desire scores
• Reduced sexual distress
• Few side effects (mild hair changes)

Subsequent trials (2010~2020):

• 4-year long-term safety confirmed (surgical menopause + estrogen + testosterone)
• Some LDL changes
• Hair·acne in some patients
• No cardiovascular event signals

FDA Approval Gap

Many male testosterone products approved (AndroGel, Testim, Androderm, etc.). Zero FDA approvals for female indication:

• Intrinsa patch (P&G): FDA submitted 2004 → 2008 approval denied (long-term cardiovascular safety concerns)
• LibiGel (BioSante): 2010s attempt → not approved due to safety data lack
• Bremelanotide (Vyleesi): FDA approved 2019 (similar indication self-injection) but limited use due to nausea·blood pressure side effects
• Flibanserin (Addyi): FDA approved 2015 (5-HT agonist). Concerns: alcohol avoidance, orthostatic hypotension

Current Clinical Application

US:

• Standardized off-label prescribing: male AndroGel divided to 1/10 female dose
• Female-dose cream/gel/patch made at compounding pharmacies
• Standard option in some menopause clinics
• Monitoring: serum testosterone every 3 months, efficacy evaluation every 6 months

Medherant TEPI Patch

Transdermal patch in development by Medherant for female-only use. Phase 1 results favorable:

• Consistent serum testosterone level maintenance
• Few side effects
• Phase 2/3 in progress

Possibility of being the first female-only FDA-approved product. Expected 2027~2028.

Korean Clinical Practice

Female testosterone prescription in Korea is very limited:

• No female indication from FDA·EMA·Korean MFDS
• Some off-label prescribing in obstetrics·endocrinology
• Divided use of male AndroGel
• Some review at menopause clinics

Side Effects·Cautions

Transdermal testosterone (female dose):

• Hair changes: some increase in facial·body hair
• Acne: in some patients
• Voice changes: very rare but irreversible risk
• Partial liver enzyme rise
• LDL changes
• Monitoring required: serum levels every 3~6 months

Natural Matrix

Natural circuits to review before testosterone prescription:

• DHEA 25~50mg/day (topical or oral): androgen precursor. Intrarosa (vaginal suppository) FDA approved
• Tongkat Ali (LJ100) 200mg: weak self-testosterone secretion stimulation
• Ashwagandha KSM-66 600mg: cortisol ↓ → testosterone balance
• Maca root: some menopausal libido RCTs
• Resistance training + adequate protein: endogenous hormone circuits
• Sleep 7~9 hours: hormone recovery

Matrix Application

HSDD diagnosis women’s sequence:

1. Exclude other causes: depression, thyroid, drugs (SSRI, OCP), relationship issues, chronic pain
2. Natural matrix: DHEA + Maca + ashwagandha + exercise + sleep
3. Estrogen (HRT) alone: partial improvement in sexual distress
4. Add testosterone (off-label): when natural matrix insufficient
5. Bremelanotide or Flibanserin: different circuit

Conclusion

Female HSDD is a clear gap in menopausal healthcare. Clinical data exist (transdermal testosterone) but FDA standard treatment is absent → gap of off-label prescription + compounding + self-prescription. Medherant TEPI patch likely becomes the first female-only standard (2027~2028). Until then, sequence of natural matrix + HRT + off-label testosterone is reasonable. Use under physician supervision + regular monitoring is essential.